Published in Gene Therapy Weekly, May 13th, 2004
"Replacing the native viral envelope protein on the surface of a retrovirus or lentivirus with the glycoprotein of a foreign enveloped virus, a process called pseudotyping, can expand the set of potential target cells for a viral vector or can restrict entry to specific cells," report scientists in the United States.
"The Ebola virus glycoprotein, because of its evolutionary origins and the route of viral entry promoted by it, possesses distinct advantages in forming the outer shell of such pseudotyped retroviruses for gene therapy applications. Studies of the transduction of human...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-05-13)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.